Pherecydes Pharma Launches a Capital Increase for c. €3m to Continue Its Clinical Development Program in Phage Therapy
Global Offering aimed at institutional investors, as well as individual investors via the PrimaryBid platform Subscription commitments totaling at least €2.3 million from longstanding shareholders
Source: finanznachrichten.de